Skip to main content
. 2009 Oct 13;27(32):5397–5403. doi: 10.1200/JCO.2008.20.6490

Fig 3.

Fig 3.

Patients with an HLA sibling donor available. (A) Disease-free survival from complete remission according to treatment arm. (B) Survival from complete remission according to treatment arm. DNR, daunorubicin; MXR, mitoxantrone; IDA, idarubicin; HR, hazard ratio; O, observed number of events.